Date published: 2026-5-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

PAQR3 Inhibitors

PAQR3 inhibitors represent a specialized class of chemicals specifically designed to target and modulate the activity of the Progestin and AdipoQ Receptor family member 3 (PAQR3), a protein that plays a pivotal role in various cellular processes. The primary mechanism of these inhibitors involves the disruption of PAQR3 function, typically by binding to its active site or allosteric sites, thereby impeding its interaction with other molecular partners or substrates. This inhibition can lead to alterations in the signaling pathways in which PAQR3 is involved. Given the complexity and multifaceted roles of PAQR3 in cellular signaling, the inhibitors are often designed to exhibit high specificity to minimize off-target effects. These chemicals are characterized by their ability to bind to PAQR3 with high affinity, a feature that is critical in achieving effective inhibition. The molecular structures of PAQR3 inhibitors are diverse, reflecting the various approaches used to block the activity of this protein. Some inhibitors are small molecules, often designed through structure-activity relationship (SAR) studies to optimize binding affinity and specificity. Others may be larger, more complex compounds that have been identified through high-throughput screening methods. The development of these inhibitors typically involves a deep understanding of PAQR3's structure and function, including knowledge of its binding sites and the conformational changes that occur upon ligand binding.

The impact of PAQR3 inhibitors on cellular signaling is profound, as PAQR3 is known to be involved in multiple signaling pathways. By inhibiting PAQR3, these chemicals can modulate the downstream effects of these pathways, which may include alterations in gene expression, protein-protein interactions, and other cellular processes. The specificity of PAQR3 inhibitors is crucial in this context, as it ensures that the intended signaling pathways are targeted while minimizing the impact on unrelated pathways. The study of these inhibitors provides valuable insights into the fundamental mechanisms by which PAQR3 regulates cellular functions. Moreover, the research into PAQR3 inhibitors contributes to the broader understanding of the role of PAQR3 in cellular physiology. These inhibitors serve as important tools in biochemical and molecular biology research, enabling scientists to dissect the complex networks of cellular signaling and to unravel the intricate mechanisms through which PAQR3 exerts its effects on cellular processes. The chemical class of PAQR3 inhibitors, therefore, represents a significant area of interest in the field of biochemistry and molecular biology, offering a window into the nuanced and dynamic world of cellular regulation.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin is a potent inhibitor of phosphatidylinositol 3-kinase (PI3K), which indirectly affects PAQR3 by altering the PI3K-AKT signaling pathway, a key regulator in many cellular processes including those influenced by PAQR3.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002 is another PI3K inhibitor, functioning similarly to Wortmannin, and indirectly impacting PAQR3 activity through the PI3K-AKT pathway.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

As an mTOR inhibitor, Rapamycin can indirectly affect PAQR3 by modulating the mTOR signaling pathway, which is interconnected with pathways regulated by PAQR3.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

Similar to U0126, PD98059 is a MEK inhibitor and can indirectly modulate PAQR3 activity through its impact on the MAPK/ERK signaling pathway.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB203580 is a p38 MAPK inhibitor and can indirectly affect PAQR3 by altering the p38 MAPK pathway, which has links to PAQR3-regulated processes.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

An inhibitor of JNK, SP600125 can indirectly modulate PAQR3 activity through the JNK signaling pathway, which interacts with PAQR3-related pathways.

Triciribine

35943-35-2sc-200661
sc-200661A
1 mg
5 mg
$104.00
$141.00
14
(1)

Triciribine specifically targets AKT, indirectly impacting PAQR3 by modulating the AKT signaling pathway, relevant to PAQR3's regulatory roles.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

As a Src family kinase inhibitor, Dasatinib can indirectly influence PAQR3 through its effects on Src family kinases, which are part of signaling networks related to PAQR3.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Imatinib, primarily known for its action on BCR-ABL, also affects c-Kit and PDGFR, indirectly influencing signaling pathways relevant to PAQR3.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Sorafenib targets multiple kinases, including RAF, and indirectly affects PAQR3 by modulating the RAF/MEK/ERK pathway.